High-dose brachytherapy for large osteosarcoma tumors
Part of Cancer clinical trials.
This trial tests a single, high-dose internal radiation treatment (brachytherapy) for large osteosarcoma tumors that can't be removed by surgery and haven't responded to other treatments. It may offer a new option for shrinking these difficult-to-treat masses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with osteosarcoma (a type of bone cancer).
- You are between 12 and 70 years old.
- The tumor cannot be removed by surgery, and other treatments (chemotherapy, targeted therapy, immunotherapy) have not worked.
- You are in good daily health (ECOG 0 or 1, meaning you can fully care for yourself).
- The tumor is large — at least 5 cm across on a scan — and can be measured.
- You agree to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
This trial tests whether combining an immunotherapy drug (atezolizumab) with focused radiation and surgery can help people whose osteosarcoma has come back only in the lungs. It aims to see if this approach is safe and may improve outcomes.
This trial tests a new drug called OMO-103, which targets a protein called Myc that helps cancer cells grow. It is for people with advanced osteosarcoma (bone cancer) that has worsened after standard chemotherapy. The drug is given intravenously (through a vein), and the study will check if it is safe and shrinks tumors.
This trial tests removing the tumor with surgery first, then following up with chemotherapy. It's for people with a new, high-grade osteosarcoma in an arm or leg that hasn't spread.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This early-phase study tests whether adding losartan to sunitinib can help control osteosarcoma that has returned or keeps growing after at least one prior treatment. It may help by targeting the cancer’s growth signals and blood supply, but the goal at this stage is mainly to check safety and find workable dosing.
Hear when a new Osteosarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.